Therapeutic oligonucleotides targeting the human MDR1 and MRP ge

Details Therapeutic oligonucleotides targeting the human MDR1 and MRP ge Therapeutic oligonucleotides targeting the human MDR1 and MRP ge

1997-09-08

1999-02-23

LeGuyader, John L.

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

435 6, 435 911, 435325, 435366, 435375, 536 231, 536 2431, C07H 2104, C12Q 168, C12N 1585

Patent

active

058745670

ABSTRACT:
The present invention provides novel compositions and methods useful in cancer therapy for inhibiting the multidrug resistance phenotype, which often thwarts long-term chemotherapeutic regimens. The novel compositions of matter comprise oligonucleotides targeted to the human MDR1 and MRP genes, which inhibit expression of these genes, thereby rendering tumors and other forms of cancer more susceptible to the cytotoxic effects of chemotherapeutic agents. Oligonucleotides are also provided that inhibit the multidrug resistance phenotype by exerting an aptameric effect.

REFERENCES:
patent: 5683987 (1997-11-01), Smith

Affiliated with

Also associated with

Rating

Therapeutic oligonucleotides targeting the human MDR1 and MRP ge does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic oligonucleotides targeting the human MDR1 and MRP ge, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic oligonucleotides targeting the human MDR1 and MRP ge will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-308412